ascopubs.org12d
Immune Checkpoint Combos in Metastatic Castration-Resistant Prostate Cancer: Where Are We Going, What Are We Doing, and Why?
Immune Checkpoint Combos in Metastatic Castration-Resistant Prostate Cancer: Where Are We Going, What Are We Doing, and Why? The following represents disclosure information provided by the author of ...
ascopubs.org12d
Journal of Clinical Oncology Podcast
The Journal of Clinical Oncology podcast, hosted by Dr. Shannon Westin and Dr. Davide Soldato, presents analyses and discussions centered on the latest findings published in ASCO’s esteemed Journal of ...
ascopubs.org12d
Time to Benefit of Androgen Deprivation Therapy in Patients With Localized Prostate Cancer Undergoing Radiotherapy
We systematically searched PubMed, Scopus, Embase, and Cochrane databases for randomized clinical trials that compared definitive radiotherapy with or without ADT in localized prostate cancer. The ...
ascopubs.org10d
Disparities in Cholangiocarcinoma Research and Trials: Challenges and Opportunities in the United States
Cancer disparities are well-established across measures of cancer incidence and mortality. Cholangiocarcinoma, a common hepatic malignancy, is no exception to these inequities. Globally and within the ...
ascopubs.org12d
Novel Computational Pipeline Enables Reliable Diagnosis of Inverted Urothelial Papilloma and Distinguishes It From Urothelial Carcinoma
Validation of Clinical Dynamic Contrast-Enhanced Magnetic Resonance Imaging Perfusion Modeling and Neoadjuvant Chemotherapy Response Prediction in Breast Cancer Using 18FDG and 64Cu-DOTA-Trastuzumab ...
ascopubs.org12d
Cancer Stories: The Art of Oncology
Embark on an intimate journey with heartfelt narratives, poignant reflections, and thoughtful dialogues, hosted by Dr. Lidia Schapira. The award-winning podcast JCO Cancer Stories: The Art of Oncology ...
ascopubs.org12d
Organ Preservation in Rectal Cancer: Fear of Risks Versus the Risks of Fear
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...
ascopubs.org21d
Using a Longformer Large Language Model for Segmenting Unstructured Cancer Pathology Reports
Preoperative Maximum Standardized Uptake Value Emphasized in Explainable Machine Learning Model for Predicting the Risk of Recurrence in Resected Non–Small Cell Lung Cancer Many Natural Language ...
ascopubs.org12d
Immune Checkpoint Combos in Metastatic Castration-Resistant Prostate Cancer: Where Are We Going, What Are We Doing, and Why?
The mainstay of treatment for patients with metastatic castration-resistant prostate cancer (mCRPC) remains a combination of androgen deprivation therapy along with standard-of-care androgen receptors ...
ascopubs.org12d
Generalized Evolutionary Classifier for Evolutionary Guided Precision Medicine
Current precision medicine (CPM) matches patients to therapies using traditional biomarkers, but inevitably resistance develops. Dynamic precision medicine (DPM) is a new evolutionary guided precision ...
ascopubs.org13d
Erratum: Real-World Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Nivolumab Plus Ipilimumab in the United States
The article by Doshi et al entitled “Real-World Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Nivolumab Plus Ipilimumab in the United States” (JCO Clin Cancer ...